|1.||Cao, Xu: 4 articles (09/2006 - 05/2005)|
|2.||Wan, Mei: 3 articles (09/2006 - 05/2005)|
|3.||Tang, Yi: 3 articles (09/2006 - 05/2005)|
|4.||Wang, Ning: 3 articles (09/2006 - 05/2005)|
|5.||Davison, Jon M: 2 articles (04/2015 - 05/2014)|
|6.||Singhi, Aatur D: 2 articles (04/2015 - 05/2014)|
|7.||Iacobuzio-Donahue, Christine A: 2 articles (11/2012 - 03/2004)|
|8.||Hruban, Ralph H: 2 articles (11/2012 - 03/2004)|
|9.||Hao, Jun: 2 articles (03/2011 - 01/2011)|
|10.||Zhou, Yingqi: 2 articles (03/2011 - 01/2011)|
07/01/2008 - "The aim of our study was to investigate whether decreased Smad2 and Smad4 protein expression in primary cervical cancers is associated with molecular alterations at 18q21.1, mutations in the functional domains of Smad2 and Smad4 or hypermethylation, and to assess the biological relevance of decreased Smad2 and Smad4 expression. "
08/01/2015 - "Considering that dosage dependence is of great importance for the role of SMAD4 protein as a tumor suppressor, potential clinical significance of SMAD4 gene promoter mutations is worth further investigation."
08/01/2015 - "The expression and intracellular localization of endogenous SMAD4 protein in selected tumor samples was studied by immunostaining and confocal microscopy. "
05/01/2014 - "Loss of SMAD4 protein expression is associated with high tumor grade and poor prognosis in disseminated appendiceal mucinous neoplasms."
11/01/2011 - "Smad4 protein was expressed in 61.5% (24/39), 53.1% (77/145), 41.3% (78/189) and 34.8% (16/46) of stage I, II, III and IV cancers, respectively. "
|2.||Colorectal Neoplasms (Colorectal Cancer)
11/01/2011 - "Smad4 protein is of no value in predicting recurrence after curative therapy in colorectal cancer, but it may be helpful in identifying a subset of patients with early recurrence after curative therapy."
02/15/2007 - "Loss of Smad4 protein expression is correlated with poor prognosis and is frequently observed in invasive and metastatic colorectal carcinoma. "
01/01/2008 - "Chromosome 18q21 deletion and Smad4 protein inactivation have been reported as molecular markers predicting unfavorable outcome in colorectal cancers and, in a previous report, we recently revealed that these molecules are closely associated with distant metastasis, which is one of the clinical factors affecting postoperative survival. "
12/04/2006 - "Smad4 protein expression level and allelic loss at 18q21 are associated with the process of liver metastasis in colorectal cancers evaluated when excluding clinical and pathological features except for liver metastasis."
12/04/2006 - "Utilising a recently developed method of immunohistochemical staining for Smad4 protein, we focused on the specific impact of Smad4 protein expression on liver metastasis in colorectal cancer. "
|4.||Neoplasm Metastasis (Metastasis)
12/04/2006 - "Chromosome 18q deletion and Smad4 protein inactivation correlate with liver metastasis: A study matched for T- and N- classification."
11/15/2012 - "Matched primary and metastasis tissues were evaluated for intragenic mutations in KRAS, CDKN2A, and TP53 and immunolabeled for CDKN2A, TP53, and SMAD4 protein products. "
01/01/2008 - "We revealed that chromosome 18q deletion and Smad4 protein inactivation are the essential molecular events in the process of lymph node metastasis."
01/01/2008 - "In this report, we studied the significance of chromosome 18q deletion and loss of Smad4 protein expression in association with lymph node metastasis. "
05/01/2007 - "Absence of Smad4 protein was more frequently observed in hepatic metastases, whether they were metachronous or synchronous, than in extrahepatic metastases (p<0.005). "
|5.||Pancreatic Neoplasms (Pancreatic Cancer)
03/25/2011 - "Moreover, ectopic expression of miR-421 significantly decreases DPC4/Smad4 protein level in pancreatic cancer cell lines and simultaneously promotes cell proliferation and colony formation in vitro. "
01/03/2011 - "Ectopic expression of miR-483-3p significantly represses DPC4/Smad4 protein levels in pancreatic cancer cell lines, and simultaneously promotes cell proliferation and colony formation in vitro. "
05/01/2005 - "SCF(beta-TrCP1) controls Smad4 protein stability in pancreatic cancer cells."
03/01/2004 - "Immunohistochemical studies for Madh4 protein in nine archival cancers (six pancreatic cancers, two duodenal cancers, and one biliary cancer) with known missense mutations indicated that all mutations within the MH1 or MH2 domain COOH-terminal to the MCR (seven of nine cases) had negative or weak labeling, whereas two cancers with mutations within the MCR had strong positive nuclear labeling for Madh4 protein. "
12/01/2001 - "Patients with pancreatic adenocarcinomas with SMAD4 protein expression had significantly longer survival (unadjusted median survival was 19.2 months as compared with 14.7 months in patients with pancreatic cancers lacking SMAD4 protein expression; P = 0.03). "
|1.||Messenger RNA (mRNA)
|2.||Transforming Growth Factor beta (TGF-beta)
|3.||Transforming Growth Factor beta1 (TGF beta 1)
|5.||Proteins (Proteins, Gene)
|6.||Transforming Growth Factor beta2
|7.||Smad Proteins (Mothers Against Decapentaplegic Homolog)
|8.||Ubiquitin-Protein Ligases (Ubiquitin-Protein Ligase)
|9.||Small Interfering RNA (siRNA)
|10.||Collagen Type I (Type I Collagen)